Hutchmed/As­traZeneca lung can­cer drug gets OK in Chi­na; Enan­ta re­ports PhIb da­ta for their oral he­pati­tis B pro­gram

A col­lab­o­ra­tion to treat non-small cell lung can­cer be­tween As­traZeneca and Hutchmed has been grant­ed ap­proval by Chi­nese reg­u­la­tors, the com­pa­ny an­nounced Tues­day.

The ap­proval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER